title: Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease.
abstract: Establishment of Helicobacter pylori infection as an etiologic agent of peptic ulcer disease and other gastric pathologies marked a revolution in gastroenterology which spurred an enormous interest in gastric physiology and immunology research. The association was soon also demonstrated in children as well. Application of antimicrobial therapies have proven remarkably efficacious in eradicating H. pylori and curing pediatric patients of duodenal ulcers as well as gastritis, negating a lifetime of ineffective therapy and life-threatening disease. Countries with high H. pylori prevalence and where H. pylori associated gastric cancer remains a primary cause of death due to cancer however would benefit from childhood vaccination. Studies in rodents and humans utilizing oral vaccination with bacterial exotoxin adjuvants demonstrated potential for limiting H. pylori colonization in the stomach. Almost 25 y of vaccine research recently culminated in a phase III clinical trial of over 4,000 children aged 6-15 y old to test an oral vaccine consisting of the H. pylori urease B subunit genetically fused to the E. coli heat labile toxin. Vaccination was demonstrated to have an efficacy of over 70%. Vaccination may now serve as an effective strategy to significantly reduce H. pylori associated disease in children throughout the world.
authors.affiliation: Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland.
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Blanchard
authors.affiliation: Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland.
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Czinn
mesh_terms: D000276:Adjuvants, Immunologic; D000293:Adolescent; D000818:Animals; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002648:Child; D017326:Clinical Trials, Phase III as Topic; D004381:Duodenal Ulcer / Q000517:prevention & control; D004926:Escherichia coli / Q000276:immunology; D005098:Exotoxins / Q000737:chemistry; D005756:Gastritis / Q000517:prevention & control*; D016481:Helicobacter Infections / Q000517:prevention & control*; D016480:Helicobacter pylori; D006801:Humans; D051379:Mice; D010437:Peptic Ulcer / Q000517:prevention & control*; D015995:Prevalence; D013274:Stomach Neoplasms / Q000517:prevention & control; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D005098:Exotoxins